Literature DB >> 20031693

Ultra-high-pressure balloon angioplasty for treatment of resistant stenoses within or adjacent to previously implanted pulmonary arterial stents.

Jessica Maglione1, Lisa Bergersen, James E Lock, Doff B McElhinney.   

Abstract

BACKGROUND: Stents are essential tools in the management of pulmonary arterial (PA) stenosis in patients with congenital heart disease. Although stents can usually be reexpanded as children grow, resistant in-stent or peri-stent obstruction can complicate the management of PA stents. Angioplasty with ultra-high-pressure (UHP) balloons may facilitate successful treatment of stent-associated PA stenoses that are resistant to high-pressure dilation. METHODS AND
RESULTS: We reviewed patients who underwent UHP angioplasty of in-stent or peri-stent PA stenoses that were resistant to high-pressure redilation. A resistant stenosis was defined as a residual balloon waist during high-pressure redilation of the stent, along with a pressure gradient and/or angiographic stenosis. Thirty-four lesions in 29 patients, including 8 with multiple concentric, overlapping, or adjacent stents, were included. The median age at UHP angioplasty was 9 years, and a median of 4 years had elapsed since unsuccessful high-pressure angioplasty. Thirty-one of the 34 (91% [81% to 100%]) UHP angioplasty procedures were successful in relieving the resistant stenosis. Balloon:waist diameter ratios were conservative (median 1.26), reflecting the ability of UHP balloons to "fracture" nearly all obstructions. After UHP dilation, lesion diameter increased by a median of 3.1 mm (36%), significantly more than after previous high-pressure dilation (1.3 mm, 19%; P<0.001). In 5 lesions, UHP angioplasty fractured the stent, allowing further vessel expansion. There were no vascular or other complications.
CONCLUSIONS: UHP angioplasty was safe and effective for treatment of stent-related resistant PA stenosis in this series; the ability to fracture maximally expanded stents may extend the utility of stents in the pediatric population.

Entities:  

Mesh:

Year:  2008        PMID: 20031693      PMCID: PMC7199106          DOI: 10.1161/CIRCINTERVENTIONS.108.826263

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  17 in total

1.  Endovascular stenting of obstructed right ventricle-to-pulmonary artery conduits: a 15-year experience.

Authors:  Lynn F Peng; Doff B McElhinney; Alan W Nugent; Andrew J Powell; Audrey C Marshall; Emile A Bacha; James E Lock
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

2.  Refinements in the implantation of pulmonary arterial stents: impact on morbidity and mortality of the procedure over the last two decades.

Authors:  Colin J McMahon; Howaida G El Said; Julie A Vincent; Ronald G Grifka; Michael R Nihill; Frank F Ing; J Kennard Fraley; Charles E Mullins
Journal:  Cardiol Young       Date:  2002-10       Impact factor: 1.093

3.  Redilation of endovascular stents in congenital heart disease: factors implicated in the development of restenosis and neointimal proliferation.

Authors:  C J McMahon; H G El-Said; R G Grifka; J K Fraley; M R Nihill; C E Mullins
Journal:  J Am Coll Cardiol       Date:  2001-08       Impact factor: 24.094

4.  Use of endovascular stents in congenital heart disease.

Authors:  M P O'Laughlin; S B Perry; J E Lock; C E Mullins
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

5.  Endovascular treatment for superior vena cava occlusion or obstruction in a pediatric and young adult population: a 22-year experience.

Authors:  Aphrodite Tzifa; Audrey C Marshall; Doff B McElhinney; James E Lock; Robert L Geggel
Journal:  J Am Coll Cardiol       Date:  2007-02-16       Impact factor: 24.094

6.  Acute and intermediate outcomes, and evaluation of injury to the aortic wall, as based on 15 years experience of implanting stents to treat aortic coarctation.

Authors:  Athar M Qureshi; Doff B McElhinney; James E Lock; Michael J Landzberg; Peter Lang; Audrey C Marshall
Journal:  Cardiol Young       Date:  2007-02-26       Impact factor: 1.093

7.  Bladed balloon angioplasty for peripheral pulmonary artery stenosis.

Authors:  Hisashi Sugiyama; Gruchen R Veldtman; Gunnar Norgard; Kyong-Jin Lee; Rajiv Chaturvedi; Lee N Benson
Journal:  Catheter Cardiovasc Interv       Date:  2004-05       Impact factor: 2.692

8.  Morphologic changes in the pulmonary arteries after percutaneous balloon angioplasty for pulmonary arterial stenosis.

Authors:  B S Edwards; R V Lucas; J E Lock; J E Edwards
Journal:  Circulation       Date:  1985-02       Impact factor: 29.690

9.  The Genesis stent: A new low-profile stent for use in infants, children, and adults with congenital heart disease.

Authors:  Thomas J Forbes; Edwin Rodriguez-Cruz; Zahid Amin; Lee N Benson; Thomas E Fagan; William E Hellenbrand; Larry A Latson; Phillip Moore; Charles E Mullins; Julie A Vincent
Journal:  Catheter Cardiovasc Interv       Date:  2003-07       Impact factor: 2.692

10.  Effect of cutting balloon angioplasty on resistant pulmonary artery stenosis.

Authors:  Lisa J Bergersen; Stanton B Perry; James E Lock
Journal:  Am J Cardiol       Date:  2003-01-15       Impact factor: 2.778

View more
  11 in total

1.  Importance of multidisciplinary management for pulmonary atresia, ventricular septal defect, major aorto-pulmonary collateral arteries and completely absent central pulmonary arteries.

Authors:  Takaya Hoashi; Satoshi Yazaki; Koji Kagisaki; Masataka Kitano; Masatoshi Shimada; Isao Shiraishi; Hajime Ichikawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-03-04

2.  Effectiveness and safety of percutaneous transcatheter implantation of pulmonary arterial stent in congenital heart disease.

Authors:  Hong Ki Ko; Young-Hwue Kim; Jeong Jin Yu; Jae-Kon Ko; In-Sook Park; Dong-Man Seo; Tae-Jin Yun; Jeong-Jun Park; Wan Sook Jang
Journal:  Korean Circ J       Date:  2012-01-31       Impact factor: 3.243

3.  Preclinical comparative assessment of a dedicated pediatric poly-L-lactic-acid-based bioresorbable scaffold with a low-profile bare metal stent.

Authors:  Kamel Shibbani; Luiza De Lima E Silva Bagno; Marie-France Poulin; Thomas Matella; Karim Diab; Clifford Kavinsky; Nagarajan Ramesh; Vinayak Bhat; Ziyad M Hijazi; Damien Kenny
Journal:  Catheter Cardiovasc Interv       Date:  2020-04-15       Impact factor: 2.692

4.  The Use and Outcomes of Small, Medium and Large Premounted Stents in Pediatric and Congenital Heart Disease.

Authors:  Brian A Boe; Jeffrey D Zampi; Kurt R Schumacher; Sunkyung Yu; Aimee K Armstrong
Journal:  Pediatr Cardiol       Date:  2016-08-27       Impact factor: 1.655

5.  Medium and long-term outcomes after bilateral pulmonary artery stenting in children and adults with congenital heart disease.

Authors:  Ismael Gonzalez; Damien Kenny; Shari Slyder; Ziyad M Hijazi
Journal:  Pediatr Cardiol       Date:  2012-07-28       Impact factor: 1.655

6.  The role of stents in the treatment of congenital heart disease: Current status and future perspectives.

Authors:  Bjoern Peters; Peter Ewert; Felix Berger
Journal:  Ann Pediatr Cardiol       Date:  2009-01

7.  Serial Versus Direct Dilation of Small Diameter Stents Results in a More Predictable and Complete Intentional Transcatheter Stent Fracture: A PICES Bench Testing Study.

Authors:  Matthew A Crystal; Gareth J Morgan; Saar Danon; Robert G Gray; Daniel H Gruenstein; Brent M Gordon; Bryan H Goldstein
Journal:  Pediatr Cardiol       Date:  2017-10-04       Impact factor: 1.655

Review 8.  Interventional cardiology in adults with congenital heart disease.

Authors:  Harsimran S Singh; Eric Horlick; Mark Osten; Lee N Benson
Journal:  Nat Rev Cardiol       Date:  2013-08-27       Impact factor: 32.419

Review 9.  Interventional Cardiology for Congenital Heart Disease.

Authors:  Damien Kenny
Journal:  Korean Circ J       Date:  2018-03-29       Impact factor: 3.243

10.  Dilating and fracturing side struts of open cell stents frequently used in pediatric cardiac interventions-An in vitro study.

Authors:  Thomas Krasemann; Marco N Kruit; Arthur E van der Mark; Martijn Zeggelaar; Michiel Dalinghaus; Ingrid M van Beynum
Journal:  J Interv Cardiol       Date:  2018-08-08       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.